ANAPTYSBIO, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
ANAPTYSBIO, INC. (ANAB) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $21.30 million for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-09-21
- ANAPTYSBIO, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $7.08M, a 23.40% decline year-over-year.
- ANAPTYSBIO, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $14.22M, a 55.05% increase year-over-year.
- ANAPTYSBIO, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $9.16M, a 11.82% increase year-over-year.
- ANAPTYSBIO, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $9.24M, a 22.47% increase year-over-year.
- ANAPTYSBIO, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $36.07M, a 5.94% increase from fiscal 2024.
- ANAPTYSBIO, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $34.05M, a 2.54% increase from fiscal 2023.
- ANAPTYSBIO, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $33.20M, a 21.38% increase from fiscal 2022.
- ANAPTYSBIO, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $27.36M, a 78.25% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.08M derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $21.30M 10-KT · filed 2026-09-21 | ||
| 2026-03-31 | $14.22M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $36.07M 10-KT · filed 2026-09-21 | |||
| 2025-09-30 | $9.16M 10-Q · filed 2025-11-04 | $18.40M derived: sum of 2 quarters · filed 2025-11-04 | $27.57M derived: sum of 3 quarters · filed 2026-05-12 | |
| 2025-06-30 | $9.24M 10-Q · filed 2025-11-04 | $18.41M derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2025-03-31 | $9.17M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | $34.05M 10-KT · filed 2026-09-21 | |||
| 2024-09-30 | $8.19M 10-Q · filed 2025-11-04 | $15.73M derived: sum of 2 quarters · filed 2025-11-04 | $25.86M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | $7.54M 10-Q · filed 2025-11-04 | $17.68M derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $10.13M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $33.20M 10-K · filed 2026-03-03 | |||
| 2023-09-30 | $7.81M 10-Q · filed 2024-11-05 | $16.23M derived: sum of 2 quarters · filed 2024-11-05 | $25.09M derived: sum of 3 quarters · filed 2024-11-05 | |
| 2023-06-30 | $8.43M 10-Q · filed 2024-11-05 | $17.29M derived: sum of 2 quarters · filed 2024-11-05 | ||
| 2023-03-31 | $8.86M 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | $27.36M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $6.27M 10-Q · filed 2023-11-02 | $12.93M derived: sum of 2 quarters · filed 2023-11-02 | $20.67M derived: sum of 3 quarters · filed 2023-11-02 | |
| 2022-06-30 | $6.66M 10-Q · filed 2023-11-02 | $14.40M derived: sum of 2 quarters · filed 2023-11-02 | ||
| 2022-03-31 | $7.74M 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | $15.35M 10-K · filed 2024-03-11 | |||
| 2021-09-30 | $4.36M 10-Q · filed 2022-11-08 | $8.05M derived: sum of 2 quarters · filed 2022-11-08 | $11.37M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $3.69M 10-Q · filed 2022-11-08 | $7.00M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $3.31M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $11.50M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $2.81M 10-Q · filed 2021-11-04 | $5.55M derived: sum of 2 quarters · filed 2021-11-04 | $8.52M derived: sum of 3 quarters · filed 2021-11-04 | |
| 2020-06-30 | $2.74M 10-Q · filed 2021-11-04 | $5.72M derived: sum of 2 quarters · filed 2021-11-04 | ||
| 2020-03-31 | $2.98M 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | $12.41M 10-K · filed 2022-03-07 | |||
| 2019-09-30 | $3.14M 10-Q · filed 2020-11-04 | $6.79M derived: sum of 2 quarters · filed 2020-11-04 | $9.65M derived: sum of 3 quarters · filed 2020-11-04 | |
| 2019-06-30 | $3.64M 10-Q · filed 2020-11-04 | $6.51M derived: sum of 2 quarters · filed 2020-11-04 | ||
| 2019-03-31 | $2.87M 10-Q · filed 2020-11-04 | |||
| 2018-12-31 | $9.96M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $2.53M 10-Q · filed 2019-11-08 | $5.08M derived: sum of 2 quarters · filed 2019-11-08 | $7.34M derived: sum of 3 quarters · filed 2019-11-08 | |
| 2018-06-30 | $2.55M 10-Q · filed 2019-11-08 | $4.81M derived: sum of 2 quarters · filed 2019-11-08 | ||
| 2018-03-31 | $2.26M 10-Q · filed 2019-11-08 | |||
| 2017-12-31 | $4.38M 10-K · filed 2020-03-02 | |||
| 2016-12-31 | $1.16M 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $604.00K 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |